Incyte Reports Q4 Earnings with Revenue Beat but EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy INCY?
Source: seekingalpha
Incyte Corp's stock fell 7.54% as it crossed below the 5-day SMA, reflecting investor concerns despite a strong revenue report.
Incyte reported Q4 total revenue of $1.51 billion, exceeding expectations by $160 million, but its earnings per share missed analyst estimates. The company provided a 2026 revenue guidance range of $4.77 billion to $4.94 billion, which is below the consensus estimate of $5.53 billion, raising concerns about future growth potential despite strong revenue growth.
The implications of this earnings report suggest that while Incyte's revenue growth is robust, the missed EPS and lower guidance may lead to cautious sentiment among investors, impacting the stock's performance in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 90.330
Low
73.00
Averages
100.31
High
125.00
Current: 90.330
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Povorcitinib Shows Significant Efficacy in Hidradenitis Suppurativa Treatment
- Significant Clinical Efficacy: The 54-week data from the STOP-HS program demonstrated that 71.4% of patients achieved HiSCR50 with povorcitinib, indicating substantial long-term efficacy in moderate to severe hidradenitis suppurativa (HS) patients, potentially transforming treatment paradigms.
- Good Safety Profile: The safety data over 54 weeks showed that treatment-emergent adverse events (TEAEs) occurred in 76.2% to 83.4% of patients, mostly mild to moderate, indicating a favorable tolerance for povorcitinib.
- Quality of Life Improvements: At Week 54, 40.5% to 46.8% of patients reported significant improvements in skin pain, and 49.0% to 58.0% experienced reductions in fatigue, suggesting that povorcitinib not only alleviates pathological symptoms but also enhances overall quality of life.
- Regulatory Application Progress: The STOP-HS data support the New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib, which are currently under review by the U.S. FDA and European Medicines Agency, indicating its potential as the first oral treatment option for HS patients.
See More
Povorcitinib Shows Significant Efficacy in HS Treatment at 54 Weeks
- Significant Clinical Efficacy: The 54-week data from the STOP-HS program show that 71.4% of patients achieved HiSCR50, indicating povorcitinib's long-term efficacy in moderate to severe hidradenitis suppurativa (HS) patients, potentially transforming treatment paradigms.
- Notable Symptom Improvement: Post-treatment, 40.5% to 46.8% of patients reported significant reductions in skin pain, while 49.0% to 58.0% experienced less fatigue, highlighting povorcitinib's positive impact on quality of life.
- Good Safety Profile: Povorcitinib's safety over 54 weeks aligns with previous 24-week data, with 76.2% to 83.4% of patients experiencing treatment-emergent adverse events, mostly mild to moderate, and serious adverse events occurring at rates below 6.4%.
- Regulatory Application Progress: The STOP-HS data support the NDA and MAA submissions for povorcitinib, currently under review by the U.S. FDA and European EMA, indicating its potential as an oral treatment option.
See More
INCYTE: PHASE 3 RESULTS FROM STOP-HS TRIAL DEMONSTRATE SUSTAINED CLINICAL EFFICACY OF POVORCITINIB THROUGH WEEK 54 IN MODERATE TO SEVERE HS PATIENTS
Phase 3 Data: Recent Phase 3 data from the STOP-HSV program indicates significant clinical efficacy in treating patients with moderate to severe herpes simplex virus (HSV) infections.
Durable Efficacy: The findings demonstrate that the treatment maintains durable clinical efficacy through week 54, suggesting long-term benefits for patients.
Patient Population: The study focused on patients experiencing moderate to severe HSV symptoms, highlighting the program's relevance to those most affected by the virus.
Implications for Treatment: These results may influence future treatment protocols and provide new options for managing HSV infections effectively.
See More
Incyte Unveils Latest Data on Povorcitinib at AAD 2026
- Clinical Data Presentation: Incyte will present 54-week efficacy and safety data for povorcitinib in hidradenitis suppurativa patients at the 2026 AAD Annual Meeting, further validating its growth potential in the inflammation and autoimmunity sector.
- Diverse Research Showcase: The conference will feature multiple ePosters for ruxolitinib cream and povorcitinib, covering atopic dermatitis, hidradenitis suppurativa, and vitiligo, highlighting Incyte's extensive research footprint in dermatological treatments.
- Promising Market Outlook: As an oral small-molecule JAK1 selective inhibitor, povorcitinib is undergoing Phase 3 trials for hidradenitis suppurativa, vitiligo, and prurigo nodularis, which are expected to create significant market opportunities for the company.
- Innovative Drug Approval: Opzelura® (ruxolitinib cream) has been approved by the FDA for the topical treatment of non-segmental vitiligo, becoming the first approved repigmentation treatment in the U.S., further solidifying Incyte's leadership in the dermatology market.
See More
Knight Therapeutics Secures New Drug Approval in Brazil
- New Indication Approved: Knight Therapeutics' Brazilian affiliate, United Medical Ltda., received ANVISA approval for MINJUVI® in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, marking a significant expansion in treatment options that is expected to greatly improve patient outcomes.
- Clinical Data Support: The approval is backed by clinical study data demonstrating meaningful response rates and durable disease control with MINJUVI® combined with R2, which is anticipated to enhance Knight's competitiveness in the Latin American market and meet the growing treatment demand.
- Strengthened Strategic Partnership: Knight entered into an exclusive supply and distribution agreement with Incyte in 2021, further solidifying its position in the Latin American market, with expectations that the promotion of MINJUVI® will increase market share and enhance the company's influence in oncology treatment.
- Positive Future Outlook: This approval not only provides Brazilian patients with a new treatment option but also showcases Knight's strong capabilities in rapid approval processes, which is expected to drive business growth in Latin America and further fulfill its commitment to high-quality cancer care.
See More
Knight Therapeutics Submits MINJUVI Supplemental Application for New Indication
- New Indication Application: Knight Therapeutics' Argentine and Mexican affiliates have submitted a supplemental application for MINJUVI® (tafasitamab) to local regulatory agencies, aiming to expand the product's applicability in the Latin American market and enhance its competitive edge.
- Market Expansion Strategy: Since signing an exclusive supply agreement with Incyte in 2021, Knight has launched MINJUVI® in Brazil, Mexico, and Argentina, planning to leverage the new indication approval to meet diverse patient needs, thereby increasing sales potential and market share.
- Clinical Data Support: In a Phase 3 clinical trial for relapsed follicular lymphoma, MINJUVI® demonstrated a significant improvement in progression-free survival, reaching 22.37 months, indicating the drug's efficacy in treatment, which may attract more physician interest.
- Future Development Outlook: Knight Therapeutics CEO Samira Sakhia emphasized that MINJUVI® represents multiple therapies rather than a single product, and with the launch of new indications, the company will continue to focus on improving patient health and driving long-term growth in the Latin American market.
See More
Povorcitinib Shows Significant Efficacy in Hidradenitis Suppurativa Treatment
- Significant Clinical Efficacy: The 54-week data from the STOP-HS program demonstrated that 71.4% of patients achieved HiSCR50 with povorcitinib, indicating substantial long-term efficacy in moderate to severe hidradenitis suppurativa (HS) patients, potentially transforming treatment paradigms.
- Good Safety Profile: The safety data over 54 weeks showed that treatment-emergent adverse events (TEAEs) occurred in 76.2% to 83.4% of patients, mostly mild to moderate, indicating a favorable tolerance for povorcitinib.
- Quality of Life Improvements: At Week 54, 40.5% to 46.8% of patients reported significant improvements in skin pain, and 49.0% to 58.0% experienced reductions in fatigue, suggesting that povorcitinib not only alleviates pathological symptoms but also enhances overall quality of life.
- Regulatory Application Progress: The STOP-HS data support the New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib, which are currently under review by the U.S. FDA and European Medicines Agency, indicating its potential as the first oral treatment option for HS patients.
See More
Povorcitinib Shows Significant Efficacy in HS Treatment at 54 Weeks
- Significant Clinical Efficacy: The 54-week data from the STOP-HS program show that 71.4% of patients achieved HiSCR50, indicating povorcitinib's long-term efficacy in moderate to severe hidradenitis suppurativa (HS) patients, potentially transforming treatment paradigms.
- Notable Symptom Improvement: Post-treatment, 40.5% to 46.8% of patients reported significant reductions in skin pain, while 49.0% to 58.0% experienced less fatigue, highlighting povorcitinib's positive impact on quality of life.
- Good Safety Profile: Povorcitinib's safety over 54 weeks aligns with previous 24-week data, with 76.2% to 83.4% of patients experiencing treatment-emergent adverse events, mostly mild to moderate, and serious adverse events occurring at rates below 6.4%.
- Regulatory Application Progress: The STOP-HS data support the NDA and MAA submissions for povorcitinib, currently under review by the U.S. FDA and European EMA, indicating its potential as an oral treatment option.
See More
INCYTE: PHASE 3 RESULTS FROM STOP-HS TRIAL DEMONSTRATE SUSTAINED CLINICAL EFFICACY OF POVORCITINIB THROUGH WEEK 54 IN MODERATE TO SEVERE HS PATIENTS
Phase 3 Data: Recent Phase 3 data from the STOP-HSV program indicates significant clinical efficacy in treating patients with moderate to severe herpes simplex virus (HSV) infections.
Durable Efficacy: The findings demonstrate that the treatment maintains durable clinical efficacy through week 54, suggesting long-term benefits for patients.
Patient Population: The study focused on patients experiencing moderate to severe HSV symptoms, highlighting the program's relevance to those most affected by the virus.
Implications for Treatment: These results may influence future treatment protocols and provide new options for managing HSV infections effectively.
See More
Incyte Unveils Latest Data on Povorcitinib at AAD 2026
- Clinical Data Presentation: Incyte will present 54-week efficacy and safety data for povorcitinib in hidradenitis suppurativa patients at the 2026 AAD Annual Meeting, further validating its growth potential in the inflammation and autoimmunity sector.
- Diverse Research Showcase: The conference will feature multiple ePosters for ruxolitinib cream and povorcitinib, covering atopic dermatitis, hidradenitis suppurativa, and vitiligo, highlighting Incyte's extensive research footprint in dermatological treatments.
- Promising Market Outlook: As an oral small-molecule JAK1 selective inhibitor, povorcitinib is undergoing Phase 3 trials for hidradenitis suppurativa, vitiligo, and prurigo nodularis, which are expected to create significant market opportunities for the company.
- Innovative Drug Approval: Opzelura® (ruxolitinib cream) has been approved by the FDA for the topical treatment of non-segmental vitiligo, becoming the first approved repigmentation treatment in the U.S., further solidifying Incyte's leadership in the dermatology market.
See More
Knight Therapeutics Secures New Drug Approval in Brazil
- New Indication Approved: Knight Therapeutics' Brazilian affiliate, United Medical Ltda., received ANVISA approval for MINJUVI® in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, marking a significant expansion in treatment options that is expected to greatly improve patient outcomes.
- Clinical Data Support: The approval is backed by clinical study data demonstrating meaningful response rates and durable disease control with MINJUVI® combined with R2, which is anticipated to enhance Knight's competitiveness in the Latin American market and meet the growing treatment demand.
- Strengthened Strategic Partnership: Knight entered into an exclusive supply and distribution agreement with Incyte in 2021, further solidifying its position in the Latin American market, with expectations that the promotion of MINJUVI® will increase market share and enhance the company's influence in oncology treatment.
- Positive Future Outlook: This approval not only provides Brazilian patients with a new treatment option but also showcases Knight's strong capabilities in rapid approval processes, which is expected to drive business growth in Latin America and further fulfill its commitment to high-quality cancer care.
See More
Knight Therapeutics Submits MINJUVI Supplemental Application for New Indication
- New Indication Application: Knight Therapeutics' Argentine and Mexican affiliates have submitted a supplemental application for MINJUVI® (tafasitamab) to local regulatory agencies, aiming to expand the product's applicability in the Latin American market and enhance its competitive edge.
- Market Expansion Strategy: Since signing an exclusive supply agreement with Incyte in 2021, Knight has launched MINJUVI® in Brazil, Mexico, and Argentina, planning to leverage the new indication approval to meet diverse patient needs, thereby increasing sales potential and market share.
- Clinical Data Support: In a Phase 3 clinical trial for relapsed follicular lymphoma, MINJUVI® demonstrated a significant improvement in progression-free survival, reaching 22.37 months, indicating the drug's efficacy in treatment, which may attract more physician interest.
- Future Development Outlook: Knight Therapeutics CEO Samira Sakhia emphasized that MINJUVI® represents multiple therapies rather than a single product, and with the launch of new indications, the company will continue to focus on improving patient health and driving long-term growth in the Latin American market.
See More
